Spinal Cord Stimulation Clinical Trials Helping Patients Find Real Relief
A patient with chronic, medication-resistant pain in their legs might enroll in a spinal cord stimulation clinical trial to test a novel electrode array placement. Such trials evaluate how precisely targeted electrical pulses delivered to the dorsal columns can modulate pain signals before they reach the brain. By comparing objective outcomes like pain scores and functional mobility between active and sham stimulation groups, researchers determine the therapy’s true efficacy and refine patient selection criteria.
Current Landscape of SCS Research
The current landscape of spinal cord stimulation (SCS) clinical trials is heavily focused on refining stimulation parameters and targeting specific neural structures to improve outcomes for chronic pain. Recent trials are moving beyond traditional paresthesia-based methods to investigate closed-loop systems and high-frequency or burst waveforms, aiming to increase responder rates for conditions like failed back surgery syndrome and painful diabetic neuropathy. A critical shift is toward objective, patient-centric endpoints, including functional improvement and reduced medication reliance, rather than solely on pain intensity scores. When considering trial participation, ask: Does this study specifically address my pain phenotype, and will the protocol allow for post-trial access to the device settings that prove effective for me?
Key Studies Shaping Pain Management Protocols
Foundational research like the SUNBURST trial directly reshaped protocols by demonstrating that 10-kHz high-frequency stimulation provided superior back pain relief without paresthesia, prompting a shift away from traditional tonic settings. Similarly, the EVOKE study’s closed-loop system, adjusting stimulation in real-time based on evoked compound action potentials, established a new standard for dynamic dose control. The SENZA-RCT then validated burst waveforms, which reduced paresthesia intolerance and improved sleep quality. These trials collectively redefined programming algorithms:
- Evidence from SUNBURST mandated high-frequency options as a first-line protocol.
- EVOKE data integrated real-time feedback loops into pain management guidelines.
- SENZA-RCT results introduced burst stimulation for patients with sensory discomfort.
Each study forced a practical update to how clinicians titrate parameters for sustained efficacy.
Emerging Indications Beyond Chronic Back Pain
Clinical trials for spinal cord stimulation are expanding beyond chronic back pain to target novel peripheral and visceral applications. Investigators are evaluating SCS for painful diabetic neuropathy, complex regional pain syndrome, and post-amputation phantom limb pain. Early phase studies also explore its utility for critical limb ischemia, where stimulation aims to improve perfusion, and for refractory angina pectoris. Additionally, trials are assessing closed-loop systems in pelvic pain syndromes and chemotherapy-induced peripheral neuropathy, focusing on patient-specific paresthesia coverage. These studies prioritize functional outcomes and quality-of-life metrics over pain scores alone.
Emerging indications in SCS clinical trials extend to neuropathy, ischemia, visceral pain, and chemotherapy sequelae, with a shift toward disease-specific, patient-centered endpoints beyond traditional back pain.
Global Trial Hubs and Patient Demographics
Global trial hubs for spinal cord stimulation (SCS) are concentrated in North America and Western Europe, where established infrastructure enables efficient patient recruitment. Demographics in these hubs skew toward older adults (typically 50–75 years) with chronic back or leg pain, often post-laminectomy. Patient demographics and trial hub location directly affect enrollment diversity; lower-income regions remain underrepresented, limiting data on ethnic and socioeconomic variability. Why do regional demographics impact SCS trial outcomes? Homogeneous patient pools in dominant hubs may mask device efficacy variations across different genetic backgrounds or pain etiologies, requiring decentralized site selection for generalizable results.
Breakthrough Trial Designs and Methodologies
In spinal cord stimulation clinical trials, breakthrough trial designs and methodologies now prioritize adaptive randomization and Bayesian statistical frameworks to dynamically adjust patient allocation based on real-time efficacy signals. These designs reduce sample sizes and trial duration by enabling early stopping for futility or success. Additionally, crossover and n-of-1 methodologies allow each participant to serve as their own control, isolating treatment effects while minimizing placebo confounds. Blinded stuttering protocols, where stimulation parameters are rapidly cycled on and off, further refine outcome measurement by masking both patients and assessors. These methodological advances enhance the reliability of pain and functional endpoint data, directly improving evidence quality for spinal cord stimulation efficacy.
Randomized Sham-Controlled Approaches
In spinal cord stimulation clinical trials, randomized sham-controlled approaches address the inherent placebo effect by employing an implanted but inactive stimulator. Patients are randomized to receive active stimulation or a sham protocol, where no current is delivered, yet all other procedural elements are identical. This design allows for rigorous, blinded comparison, isolating the true neurophysiological impact of stimulation from patient expectation. A critical element is the robust blinding integrity required, as participants must remain unaware of their allocation to prevent unblinding through paresthesia. Outcomes are assessed objectively, with data from sham groups providing a baseline to quantify genuine pain relief efficacy beyond placebo response.
Adaptive and Bayesian Designs for Faster Results
Adaptive and Bayesian designs are speeding up spinal cord stimulation trials by letting researchers adjust the trial mid-course. Instead of sticking to a fixed plan, you can drop ineffective stimulation settings early or shift more patients to promising ones. This means faster identification of optimal parameters for pain relief, as Bayesian methods use prior data to make real-time decisions with smaller patient groups. Results are practical: you spend less time in lengthy studies and get clearer answers on what works. Q: How do these designs cut trial time? A: They use accumulating data to stop weak arms early and focus resources on the most effective stimulation patterns.
Real-World Evidence vs. Traditional RCTs
Traditional RCTs for spinal cord stimulation (SCS) remain the gold standard for causal efficacy, yet their rigid inclusion criteria often exclude complex chronic pain patients seen in practice. Real-world evidence (RWE) fills this gap by capturing heterogeneous populations and long-term outcomes across diverse clinical settings, enabling more generalizable insights. RWE complements RCTs by providing pragmatic data on device durability, reprogramming frequency, and medication reduction over years, not just months. This synergy allows clinicians to better predict patient-specific responses and refine trial parameters for improved clinical utility.
- RWE leverages registry and EHR data to validate SCS performance in real-world patient populations with comorbidities often excluded from RCTs.
- Unlike fixed RCT protocols, RWE tracks therapy adjustments (e.g., lead revisions, stimulation pattern changes) that reflect actual clinical decision-making.
- RWE datasets can identify which patient subgroups derive sustained analgesia beyond RCT follow-up periods, informing long-term treatment strategies.
Patient-Specific Outcomes and Selection Criteria
Patient-specific outcomes in spinal cord stimulation (SCS) trials hinge on rigorously defined selection thync.com criteria, primarily targeting neuropathic pain with confirmed spinal or peripheral nerve injury. Ideal candidates present with failed conservative management and have no untreated psychiatric comorbidities, active coagulopathy, or untreated addiction. A key predictor is a positive response to trial stimulation, typically defined as ≥50% pain relief on a validated scale, alongside demonstrated functional improvement (e.g., walking distance, sleep quality). Avoid selecting patients with predominant mechanical or inflammatory pain, as SCS efficacy is limited here.
Trials should use patient-specific diaries and quantitative sensory testing to objectively map outcome thresholds, ensuring that only those with sustained, measurable benefit proceed to implantation.
Strict adherence to these criteria prevents poor surgical outcomes and reduces explant rates by aligning device therapy with biological pain mechanisms.
Predictive Biomarkers for Stimulation Success
In spinal cord stimulation clinical trials, predictive biomarkers for stimulation success are being rigorously evaluated to refine patient selection. Electroencephalographic markers, such as pre-treatment alpha-band power, show promise in forecasting analgesic response. Additionally, quantitative sensory testing metrics, including conditioned pain modulation capacity, may identify individuals with central sensitization profiles amenable to neuromodulation. These biomarkers, when integrated into trial protocols, reduce cohort heterogeneity and improve the likelihood of detecting a true treatment effect. The ultimate goal is to move beyond trial-and-error implantation by using predictive biomarkers for stimulation success to pre-specify candidates who will achieve durable pain relief, thereby enhancing trial efficiency and clinical translation.
Psychological Screening in Enrollment Protocols
Psychological screening in enrollment protocols for spinal cord stimulation clinical trials filters candidates by identifying traits like catastrophizing or somatization, which can undermine trial fidelity. A structured multi-step evaluation typically begins with validated tools such as the MMPI-2 to flag mood disorders. Next, a clinician-led interview assesses coping strategies and treatment expectations. Finally, a consensus review excludes individuals with active psychosis or unresolved trauma. This process targets candidate psychological viability, ensuring only resilient participants progress to device implantation, thereby reducing dropout and placebo-response bias.
- Administer psychometric questionnaires to screen for anxiety or depression.
- Conduct a structured interview to gauge adherence readiness.
- Review findings for exclusion criteria like substance abuse history.
Pain Type Categorization and Subgroup Analysis
In spinal cord stimulation clinical trials, pain type categorization and subgroup analysis refines patient selection by distinguishing neuropathic, nociceptive, and mixed pain phenotypes. Trials often use validated tools (e.g., DN4 or PainDETECT) to stratify participants, as neuropathic pain typically shows superior response to stimulation. Subgroup analysis examines variables like pain distribution (focal vs. diffuse) or comorbid psychological profiles to predict outcome heterogeneity. This stratification helps identify non-responders early, reducing placebo confounds in efficacy endpoints.
| Aspect | Neuropathic Pain | Mixed Pain |
|---|---|---|
| Typical SCS response | ≥50% pain relief in 60-70% of patients | ~40-50% response rate, often requiring trial optimization |
| Subgroup focus | Allodynia or hyperalgesia patterns | Ratio of neuropathic to nociceptive components |
Technology Innovations Under Investigation
Researchers are currently testing closed-loop spinal cord stimulation systems that adjust pulse parameters in real time based on your body’s feedback, aiming to stop pain before it peaks. Another area under investigation involves targeted fiber-selective waveforms, designed to activate only pain-blocking nerve fibers while avoiding motor twitches. Clinical trials are also exploring ultra-high-frequency bursts (like 10 kHz) delivered through novel electrode arrays that curve around the spinal cord for better coverage. Some studies are trialing small, battery-free implants powered wirelessly, reducing the need for replacement surgeries. These tech innovations focus squarely on making daily pain relief more consistent and less intrusive.
Closed-Loop Systems and Real-Time Neural Feedback
In spinal cord stimulation clinical trials, closed-loop systems leverage real-time neural feedback to dynamically adjust stimulation parameters based on recorded spinal or cortical activity. This adaptive neurostimulation paradigm enables instantaneous modulation of pulse amplitude or frequency in response to detected electrophysiological biomarkers, such as dorsal column action potentials or local field potentials. By continuously matching stimulation delivery to the patient’s fluctuating neural state, these systems aim to reduce habituation and improve pain relief consistency. Clinical protocols now incorporate algorithms that decode neural signatures to trigger or withhold stimulation, creating a responsive loop that optimizes therapeutic efficacy without manual recalibration.
High-Frequency and Burst Waveform Comparisons
In clinical trials, high-frequency and burst waveform comparisons are critical for optimizing patient outcomes. High-frequency (10 kHz) stimulation delivers paresthesia-free relief by targeting dorsal horn pathways, while burst patterns mimic neural firing with passive charge recovery, yielding distinct limbic system activation. Early data suggests burst may better modulate emotional-affective components of pain, though high-frequency excels in covering axial back pain. Comparative trials measure difference in pain scores, comfort, and preference. Key aspects include:
| Waveform | Key Mechanism | Primary Advantage |
|---|---|---|
| High-Freq | 10 kHz dorsal horn activation | Superior axial coverage |
| Burst | Spike-burst firing & limbic engagement | Enhanced emotional pain relief |
Miniaturized Lead Placement and MRI Compatibility
In clinical trials, miniaturized lead placement is making the procedure less invasive by using thinner, more flexible wires inserted through a single needle. This smaller footprint eases the recovery process. Crucially, these new leads are designed for full-body MRI compatibility, letting patients undergo scans without the strict restrictions of older systems. Instead of removing the device, the trial is testing leads that can safely stay active during imaging, which is a huge practical win for routine medical care.
Will these miniaturized leads work with any MRI machine? The trials focus on 1.5T and 3T scanners, the most common types in hospitals, so you’re covered for typical scans.
Safety and Adverse Event Tracking
During the trial, each participant’s experience with the implanted device was meticulously logged. Adverse events, such as lead migration or infection at the incision site, were tracked in real-time using a standardized severity scale, prompting immediate clinical intervention protocols. For one subject who reported sudden, radiating pain, the event was correlated with a postural adjustment noted in their daily diary. Neurological assessments were scheduled at every follow-up to capture any subtle motor or sensory changes that might signal unintended nerve damage from the electrical field. The true challenge lay in distinguishing device-related events from the natural progression of the underlying neuropathic condition. All data was reviewed by an independent monitoring board to ensure patient safety thresholds were never breached.
Long-Term Infection and Lead Migration Rates
Long-term infection rates in spinal cord stimulation clinical trials are tracked over multi-year follow-ups, with reported incidences typically below 5% and often linked to pocket or lead-tract issues. Lead migration, a distinct mechanical complication, occurs in approximately 2–10% of cases, frequently within the first six months post-implant. Both events show correlations with surgical technique and patient activity levels. Surveillance protocols assess migration via imaging and impedance changes, while infections are monitored through culture data and explant rates. Understanding lead migration thresholds is critical for programming adjustments and revision decisions.
Neurological Deficit Monitoring in Trials
In spinal cord stimulation trials, neurological deficit monitoring involves serial, protocol-mandated assessments to detect new motor or sensory changes early. This typically follows a clear sequence:
- Baseline neurological exams are conducted pre-implant to map each patient’s existing function.
- Post-surgical checks occur within hours to identify acute cord changes, such as new weakness or numbness.
- Systematic follow-ups then track any persistent or emerging deficits, enabling rapid device adjustment or lead revision before permanent injury develops.
This real-time vigilance ensures patient safety during the trial period.
Battery Life and Device Failure Documentation
In spinal cord stimulation trials, documenting battery life and device failure patterns is crucial for participant safety. Teams log battery depletion rates, recharging habits, and any sudden power drops to catch early signs of failure. If an implant dies prematurely, that gets noted alongside symptoms like loss of stimulation or unexpected shocks. A common question: What happens if my device fails during the trial? You’d report it immediately, and the team records the failure type, duration, and any related discomfort to track recurring issues. This documentation helps refine future device reliability and keeps you informed.
Regulatory and Reimbursement Pathways
Before a spinal cord stimulation trial can begin, the investigational device must navigate the FDA’s Investigational Device Exemption, which requires proof of sufficient preclinical safety data to allow human implantation. Once the trial proves efficacy, the next hurdle is securing a new or existing CPT code for the trial procedure itself, as insurers will not reimburse without a billable pathway. Yet even a successful code can stall adoption if private payers demand additional comparative effectiveness data before granting broader coverage. Reimbursement hinges on the trial’s ability to demonstrate that the therapy reduces downstream costs—like fewer opioid prescriptions or repeat surgeries—convincing Medicare Administrative Contractors to assign a favorable fee schedule. Without these regulatory and reimbursement steps locked in, even a clinically successful SCS trial remains inaccessible to patients outside the study.
FDA Breakthrough Device Designation Impact
In spinal cord stimulation clinical trials, FDA Breakthrough Device Designation Impact centers on accelerated trial design and earlier patient access. This designation permits device developers to engage the FDA in more iterative feedback cycles, allowing protocol adjustments based on interim safety and efficacy data rather than waiting for full trial completion. For trial participants, this often means faster enrollment in studies testing novel stimulation parameters or electrode configurations for chronic pain, as the designation streamlines Investigational Device Exemption (IDE) requirements. Conversely, it imposes stringent real-world evidence collection demands during and after the trial to support eventual premarket approval, ensuring that the accelerated pathway does not compromise outcome validation.
In trial settings, the designation accelerates regulatory feedback and enrollment speed while requiring rigorous post-study evidence generation.
CMS Coverage Decisions Influencing Recruitment
CMS coverage decisions directly shape recruitment by defining which patient populations and trial designs are financially viable for sponsors. A local coverage determination restricting SCS therapy to failed back surgery syndrome, for example, compels trials to exclude chronic pain patients without prior surgery, narrowing the eligible pool. Conversely, a national coverage analysis that permits enrollment for conditions like complex regional pain syndrome expands recruitment targets. Trial protocols must align with these coverage parameters to ensure procedures are reimbursed, otherwise sites may decline participation due to financial risk. This linkage forces investigators to pre-emptively design inclusion criteria that mirror existing CMS payment rules, making coverage policy a de facto recruitment gatekeeper.
Multinational Approval Timelines and Harmonization
For spinal cord stimulation trials, you’ll face varying approval timelines across countries—some agencies clear protocols in weeks, while others take months. Multinational harmonization initiatives help, letting you submit a single dossier to multiple ethics committees, though local endpoints still differ. Decentralized approvals mean a tweak for one country’s requirements rarely transfers to another, extending your timeline. A practical strategy is to align your trial design with ICH-GCP early, which some regulators recognize for faster reviews.
| Aspect | Timeline Impact |
| Single submission (harmonized) | Weeks saved |
| Per-country resubmissions | Months added |
Patient Recruitment and Retention Strategies
Effective patient recruitment and retention strategies for spinal cord stimulation clinical trials must directly address the unique burden of chronic pain. Reduce dropout risk by integrating trial visits with patients’ existing pain management schedules and offering flexible telemedicine follow-ups for diary entries and device adjustments. Clearly communicate the realistic benefits of potential paresthesia coverage versus sham control, and provide robust support for surgical-site care and battery charging to mitigate early discontinuation. Building trust through dedicated trial coordinators who guide patients through programming sessions and troubleshooting ensures consistent long-term engagement. Prioritizing a streamlined, patient-centric experience from screening through final follow-up directly improves data integrity and trial completion rates.
Decentralized Trial Models Using Wearables
For spinal cord stimulation trials, decentralized trial models using wearables convert a static clinic visit into continuous, real-world data capture. A typical sequence involves:
- Patients receive a smartwatch or patch sensor that logs gait, activity levels, and sleep patterns alongside stimulator usage.
- This data transmits automatically to a secure cloud portal, replacing paper diaries and reducing recall bias.
- Remote symptom surveys trigger only if wearable metrics deviate from baseline, allowing clinicians to adjust stimulation parameters without requiring a site visit.
This model keeps participants engaged at home, eliminating travel burdens while collecting high-fidelity pain and mobility outcomes directly relevant to device efficacy.
Informed Consent and Expectation Management
In spinal cord stimulation trials, informed consent and expectation management must bridge the gap between clinical possibility and lived reality. Patients need concrete illustrations of paresthesia patterns and trial stimulation sensations, not vague promises of relief. The consent process actively recalibrates hopes by detailing the temporary nature of the trial phase alongside potential side effects like temporary motor twitching. We guide participants to view « success » as a measurable reduction in pain scores rather than total elimination, using daily diaries to anchor expectations to specific, actionable outcomes. This upfront honesty prevents early dropout and builds the trust needed for sustained engagement through programming adjustments.
Dropout Reduction Through Remote Monitoring
Remote monitoring directly tackles dropout in spinal cord stimulation trials by letting participants report symptoms and device usage from home. This reduces the burden of frequent clinic visits, which often causes early exits. Real-time data alerts coordinators to issues like waning compliance or discomfort, allowing quick interventions. At-home device logging keeps patients engaged between appointments, making them feel supported rather than neglected. Q: How does remote monitoring cut dropouts in SCS trials? A: It catches problems early—like reduced stimulation use—and lets patients stay in the study without constant travel, so they stick with it longer.
Future Directions and Unmet Needs
Future directions in spinal cord stimulation clinical trials must prioritize personalized stimulation parameters that adapt to real-time neural feedback, addressing the unmet need for dynamic rather than static programming. Trials should investigate closed-loop systems capable of modulating output based on patient posture or activity, a critical gap in current protocols. Another unmet need is robust, long-term outcome data for specific etiologies like post-surgical or diabetic neuropathy, as most trials aggregate heterogeneous pain populations. Future studies must also standardize objective functional endpoints beyond subjective pain scores, such as gait analysis or quantitative sensory testing, to validate efficacy. Without these targeted designs, clinical translation remains hampered by unresolved questions about optimal patient selection and durable symptom control.
Pediatric and Geriatric Trial Gaps
Clinical trial gaps for pediatric and geriatric spinal cord stimulation leave these vulnerable populations without evidence-based protocols. Pediatric trials are absent, lacking safety data on lead migration during growth or optimal stimulation parameters for developing neuroanatomy. Geriatric trials are scarce, with no validated titration strategies for age-related neuroplasticity, polypharmacy interactions, or cognitive impairment’s effect on feedback accuracy. Existing adult norms fail to account for reduced pain tolerance, frailty-related implant risks, or comorbid sensory deficits in the elderly. This absence forces clinicians to extrapolate from adult data—a practice unsupported by trial design—generating uncertain outcomes for both age extremes.
| Aspect | Pediatric Gap | Geriatric Gap |
|---|---|---|
| Safety data | No lead migration or growth-adjusted studies | No frailty or polypharmacy interaction trials |
| Parameter validation | Missing age-specific amplitude/rate sets | No adaptive protocols for cognitive decline |
| Efficacy endpoints | Unvalidated pain scales for children | Outcomes unadjusted for comorbid sensory loss |
Neurostimulation for Visceral and Ischemic Pain
Expanding spinal cord stimulation (SCS) into neurostimulation for visceral and ischemic pain addresses critical clinical voids. Current SCS trials are pioneering targeted waveforms to modulate splanchnic pathways for chronic pancreatitis and pelvic pain, while pioneering high-frequency bursts aim to improve microcirculation in refractory angina and peripheral arterial disease. A prime unmet need is validating durable efficacy against visceral hypersensitivity and limb-threatening ischemia. Can neurostimulation for visceral and ischemic pain reliably prevent amputations or reduce opioid use in these fragile populations? Early data suggest yes, but multi-center comparative trials must confirm long-term perfusion changes and pain suppression without off-target motor effects.
Combination Therapies with Pharmacologics
Future trials must prioritize combination therapies with pharmacologics to address suboptimal SCS responders. Current protocols isolate SCS from concomitant drugs like gabapentinoids or NSAIDs, masking additive or synergistic effects. Systematic investigation should map pharmacokinetic interactions, determining whether lower drug doses maintain analgesia under SCS. Trials need to standardize washout periods and measure serum levels to distinguish SCS-driven relief from pharmacologic action. Without this, dose-dependent adverse events remain unquantified, and patients may receive redundant polypharmacy that undermines SCS efficacy. Rigorous factorial-design studies can isolate the true therapeutic contribution of each component.
Combination therapies with pharmacologics require controlled trials to quantify additive efficacy, minimize polypharmacy risks, and establish evidence-based drug-SCS pairing protocols.
Data Transparency and Publication Bias
In spinal cord stimulation trials, data transparency means making all results publicly available, not just the positive ones. The catch? Publication bias often hides negative or neutral outcomes, skewing our understanding of what truly works. For example, a study might show reduced pain, but if ten others showing no benefit go unpublished, we get a lopsided view. Q: How does publication bias affect my treatment choice? A: It can make a therapy seem more effective than it is, since you’re only seeing the success stories. Always check trial registries for unpublished data before committing.
Pre-Registration of Protocols on ClinicalTrials.gov
Pre-registration of protocols on ClinicalTrials.gov mitigates publication bias in spinal cord stimulation trials by time-stamping primary outcomes and analysis plans before enrollment. This prevents post-hoc switching of endpoints to favor stimulator efficacy or pain reduction. For practitioners, verifying pre-registration ensures a trial’s results are not selectively reported. A completed record on ClinicalTrials.gov should specify stimulation parameters (e.g., frequency, lead location) and primary pain measures (e.g., VAS, ODI). Without it, a published positive outcome cannot be reliably compared against its original hypothesis.
Negative Result Reporting and Meta-Analyses
In spinal cord stimulation trials, negative result reporting is often skipped, which skews meta-analyses. When unpublished or null findings are left out, meta-analyses overestimate treatment benefits, misleading clinicians. For a fair view, meta-analyses must actively seek negative results from registries or authors. This creates balanced meta-analysis data for SCS. Without this effort, a meta-analysis becomes a lopsided summary of only positive outcomes.
| Aspect | Negative Result Reporting | Meta-Analyses |
|---|---|---|
| Role | Fills publication gaps | Aggregates all results |
| Risk if omitted | Bias stays hidden | Overestimates efficacy |
Industry Sponsorship Influence on Trial Outcomes
Industry sponsorship in spinal cord stimulation trials creates a tangible skew toward favorable outcomes. Funded studies are more likely to report positive results for the sponsor’s device, often because of comparative bias in trial design, such as using weak control groups or short follow-up periods. This influence can mask modest efficacy or higher complication rates. For patients, this means published success rates may not reflect real-world results, potentially leading to overestimated expectations during shared decision-making.
- Sponsor-backed trials frequently omit head-to-head comparisons with competitor devices.
- Negative outcomes or non-superiority results are less likely to be published or emphasized.
- Patient selection criteria in funded studies may favor milder symptom profiles to boost success rates.
